In the concall, Management mentioned they will focus on productivity and no significant capex for next couple of years, other than the usual R&D expense. Chronic segment continues > 20% growth but current pain is price deflation (~20%) in US market. Also, they are testing the waters in CDMO and did not show any enthusiasm. Biosimilars part is only starting now and expected to reach ~500 Cr by 2026 (5% revenue in 4 years). Overall this doesn’t look very exciting and may grow by the usual 10-12% (as per history) and hand-in-hand with IPM growth (similar or higher expected).
What are the growth triggers for Alkem from here that I may have missed?
Invested.
| Subscribe To Our Free Newsletter |
